LUANDA MARA DA SILVA OLIVEIRA

(Fonte: Lattes)
Índice h a partir de 2011
13
Lattes
Projetos de Pesquisa
Unidades Organizacionais
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Indexador: PubMed ×

Resultados de Busca

Agora exibindo 1 - 3 de 3
  • article 33 Citação(ões) na Scopus
    Delivery of microRNAs by Extracellular Vesicles in Viral Infections: Could the News be Packaged?
    (2019) YOSHIKAWA, Fabio Seiti Yamada; TEIXEIRA, Franciane Mouradian Emidio; SATO, Maria Notomi; OLIVEIRA, Luanda Mara da Silva
    Extracellular vesicles (EVs) are released by various cells and recently have attracted attention because they constitute a refined system of cell-cell communication. EVs deliver a diverse array of biomolecules including messenger RNAs (mRNAs), microRNAs (miRNAs), proteins and lipids, and they can be used as potential biomarkers in normal and pathological conditions. The cargo of EVs is a snapshot of the donor cell profile; thus, in viral infections, EVs produced by infected cells could be a central player in disease pathogenesis. In this context, miRNAs incorporated into EVs can affect the immune recognition of viruses and promote or restrict their replication in target cells. In this review, we provide an updated overview of the roles played by EV-delivered miRNAs in viral infections and discuss the potential consequences for the host response. The full understanding of the functions of EVs and miRNAs can turn into useful biomarkers for infection detection and monitoring and/or uncover potential therapeutic targets.
  • conferenceObject
    Early Biomarkers to Predict a Worse Outcome After Acute Myocardial Infarction: Circulating Infectious Extracellular Vesicles From Archaea and M. Pneumoniae Are Present and Correlated to Cytokines IL-6 and IL-10
    (2022) MORENO, Camila R.; SOEIRO, Alexandre M.; SATO, Maria N.; PEREIRA, Jaqueline J.; IKEGAMI, Renata N.; KAWAKAMI, Joyce T.; REIS, Marcia M.; OLIVEIRA, Luanda M.; HIGUCHI, Maria Lourdes
  • article 2 Citação(ões) na Scopus
    Morphomolecular Characterization of Serum Nanovesicles From Microbiomes Differentiates Stable and Infarcted Atherosclerotic Patients
    (2021) MORENO, Camila Rodrigues; RAMIRES, Jose Antonio Franchini; LOTUFO, Paulo Andrade; SOEIRO, Alexandre Matos; OLIVEIRA, Luanda Mara da Silva; IKEGAMI, Renata Nishiyama; KAWAKAMI, Joyce Tiyeko; PEREIRA, Jaqueline de Jesus; REIS, Marcia Martins; HIGUCHI, Maria de Lourdes
    Microbial communities are considered decisive for maintaining a healthy situation or for determining diseases. Acute myocardial infarction (AMI) is an important complication of atherosclerosis caused by the rupture of atheroma plaques containing proinflammatory cytokines, reactive oxygen species, oxidized low-density lipoproteins (oxLDL), damaged proteins, lipids, and DNA, a microenvironment compatible with a pathogenic microbial community. Previously, we found that archaeal DNA-positive infectious microvesicles (iMVs) were detected in vulnerable plaques and in the sera of Chagas disease patients with heart failure. Now, we characterize and quantify the levels of serum microbiome extracellular vesicles through their size and content using morphomolecular techniques to differentiate clinical outcomes in coronary artery disease (CAD). We detected increased numbers of large iMVs (0.8-1.34 nm) with highly negative surface charge that were positive for archaeal DNA, Mycoplasma pneumoniae antigens and MMP9 in the sera of severe AMI patients, strongly favoring our hypothesis that pathogenic archaea may play a role in the worst outcomes of atherosclerosis. The highest numbers of EVs <100 nm (exosomes) and MVs from 100 to 200 nm in the stable atherosclerotic and control healthy groups compared with the AMI groups were indicative that these EVs are protective, entrapping and degrading infectious antigens and active MMP9 and protect against the development of plaque rupture. Conclusion: A microbiome with pathogenic archaea is associated with high numbers of serum iMVs in AMI with the worst prognosis. This pioneering work demonstrates that the morphomolecular characterization and quantification of iEVs in serum may constitute a promising serum prognostic biomarker in CAD.